Elanco's Zenrelia is now competing in the market against Zoetis' Apoquel.
2 reports, 2 independent
Updated Aug 5
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Elanco's Zenrelia is now competing in the market against Zoetis' Apoquel.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- USANA Health Sciences has better valuation metrics than Zoetis.Sub-event
Elanco's Zenrelia competes with Zoetis' Apoquel.1 source
Elanco's Zenrelia received approval for canine dermatitis treatment.1 source
Keep exploring
The entities involved
-
Zoetis
American animal health company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Motley Fool1 Top Dividend Growth Stock to Buy and Hold Forever Zoetis has hit a road bump due to increased competition in one of its niches. The animal health company has the tools to get over this challenge an
- StockStoryWhy Elanco (ELAN) Stock Is Trading Up Today Shares of animal health company Elanco (NYSE:ELAN) jumped 3% in the pre-market session after the company received approval from the European Commission for